The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies.
With major facilities in Australia, Germany, Switzerland and the US, CSL employs over 13,000 employees working in 27 countries.
Our Areas of Expertise
Human plasma is used to produce a wide range of life-saving medicines.
Our various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma-derived products.
The key businesses involved with plasma products include:
CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through
CSL Behring (Australia) is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. We also manufacture and market in vitro diagnostic products through bioCSL
Vaccines & Pharmaceuticals
We manufacture and provide influenza vaccine globally.
In Australia and New Zealand,
bioCSL also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.
Research & Development
Our activities at CSL are focused on new product development, life-cycle management and safety of our extensive product portfolio. CSL invests in the development of protein-based medicines for treating serious human diseases. Medicines can be made from plasma, traditional biological sources or using recombinant biotechnology. More information is available in the
Research & Development section.